Trial Profile
A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms DANUBE
- Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca KK
- 08 Mar 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 08 Feb 2024 This trial has been completed in Germany.
- 21 Dec 2023 Planned End Date changed from 29 Mar 2024 to 30 Dec 2024.